PL354282A1 - Vasopressin antagonist formulation and process - Google Patents

Vasopressin antagonist formulation and process

Info

Publication number
PL354282A1
PL354282A1 PL00354282A PL35428200A PL354282A1 PL 354282 A1 PL354282 A1 PL 354282A1 PL 00354282 A PL00354282 A PL 00354282A PL 35428200 A PL35428200 A PL 35428200A PL 354282 A1 PL354282 A1 PL 354282A1
Authority
PL
Poland
Prior art keywords
vasopressin antagonist
antagonist formulation
formulation
vasopressin
antagonist
Prior art date
Application number
PL00354282A
Other languages
English (en)
Polish (pl)
Inventor
Joseph KyuwungYoon Joseph Kyuwung Yoon
Richard WilliamSaunders Richard William Saunders
Mahdi BakirFawzi Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Companyamerican Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Companyamerican Cyanamid Company filed Critical American Cyanamid Companyamerican Cyanamid Company
Publication of PL354282A1 publication Critical patent/PL354282A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00354282A 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process PL354282A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Publications (1)

Publication Number Publication Date
PL354282A1 true PL354282A1 (en) 2003-12-29

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354282A PL354282A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Country Status (18)

Country Link
EP (1) EP1216033A1 (no)
JP (1) JP2003510269A (no)
KR (1) KR20020039354A (no)
CN (1) CN1391466A (no)
AR (1) AR025780A1 (no)
AU (1) AU7615000A (no)
BR (1) BR0014351A (no)
CA (1) CA2388474A1 (no)
CZ (1) CZ20021083A3 (no)
EA (1) EA200200414A1 (no)
HK (1) HK1045109A1 (no)
HU (1) HUP0202972A3 (no)
IL (1) IL148541A0 (no)
MX (1) MXPA02003189A (no)
NO (1) NO20021475L (no)
PL (1) PL354282A1 (no)
WO (1) WO2001022945A1 (no)
ZA (1) ZA200203312B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
CZ20021083A3 (cs) 2002-06-12
KR20020039354A (ko) 2002-05-25
CN1391466A (zh) 2003-01-15
NO20021475D0 (no) 2002-03-25
AR025780A1 (es) 2002-12-11
AU7615000A (en) 2001-04-30
IL148541A0 (en) 2002-09-12
HUP0202972A3 (en) 2003-07-28
EA200200414A1 (ru) 2002-12-26
CA2388474A1 (en) 2001-04-05
NO20021475L (no) 2002-04-16
HK1045109A1 (zh) 2002-11-15
MXPA02003189A (es) 2002-09-30
WO2001022945A1 (en) 2001-04-05
JP2003510269A (ja) 2003-03-18
BR0014351A (pt) 2002-06-11
HUP0202972A2 (hu) 2002-12-28
ZA200203312B (en) 2003-12-31
EP1216033A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
HUP0201489A3 (en) New formulation
HK1044329A1 (en) Concrete formulation
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
IL146230A0 (en) 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EG24226A (en) Formulation
GB9909898D0 (en) Cleaning compositions and tablets
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AU7615200A (en) Vasopressin agonist formulation and process
IL148541A0 (en) Vasopressin antagonist formulation and process
GB9909154D0 (en) Pharmaceutical formulation
GB9927614D0 (en) Sterliant formulation
GB9926251D0 (en) Pharmaceutical formulation
AU1623801A (en) Opioid metallopeptide compositions and methods
GB9902236D0 (en) Formulation
GB9908776D0 (en) Formulation
GB9902089D0 (en) Formulation
GB9917952D0 (en) Formulation
GB9915584D0 (en) Formulation
GB9923538D0 (en) Formulation
AU7615100A (en) Vasopressin antagonist and diuretic combination
IL132705A0 (en) Compounds and pharmaceutical compositions comprising same
GB9930700D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)